Page 182 - Educacional Ponenecias Congreso SEHH-STH 2020

13. Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gug- liotta G, et al. Next-generation sequencing for sensitive detection of BCR- ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resis- tant patients. Oncotarget. 2016;7(16):21982-90.
14. Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jarus- kova M, et al. Next-generation deep sequencing improves detection of BCR- ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887-99.
15. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic my- elogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-8.
16. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid
leukemia patients receiving imatinib therapy. Haematologica. 2013;98:
193-200.
17. Ng K, Hillmer A, Chuah C, Juan WC, Ko TK, Teo AS, et al. A common BIM dele-
tion polymorphism mediates intrinsic resistance and inferior responses to
tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521-8.
18. Alonso-Domínguez JM, Casado LF, Anguita E, Gómez-Casares MT, Buño I, Ferrer-Marín F,et al. PTCH1 is a reliable marker for predicting imatinib re- sponse in chronic myeloid leukemia patients in chronic phase. PLoS One.
2017;12(7):e0181366.
19. KimT,Tyndel MS,Kim HJ,Ahn JS,Choi SH,Park HJ,et al.Spectrum of somatic
mutation dynamics in chronic myeloid leukemia following tyrosine kinase
inhibitor therapy. Blood. 2017;129(1):38-47.
20. Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, et al.
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haemato- logica. 2019;104(12):2400-9.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
182